TY  - JOUR
A1  - Buck, Andreas
A1  - Decristoforo, Clemens
T1  - Highlights lecture EANM 2015: the search for nuclear medicine's superheroes
JF  - European Journal of Nuclear Medicine and Molecular Imaging
N2  - The EANM 2015 Annual Congress, held from October 10th to 14th in Hamburg, Germany, was outstanding in many respects. With 5550 participants, this was by far the largest European congress concerning nuclear medicine. More than 1750 scientific presentations were submitted, with more than 250 abstracts from young scientists, indicating that the future success of our discipline is fuelled by a high number of young individuals becoming involved in a multitude of scientific activities. Significant improvements have been made in molecular imaging of cancer, particularly in prostate cancer. PSMA-directed PET/CT appears to become a new gold standard for staging and restaging purposes. Novel tumour specific compounds have shown their potential for target identification also in other solid neoplasms and further our understanding of tumour biology and heterogeneity. In addition, a variety of nuclear imaging techniques guiding surgical interventions have been introduced. A particular focus of the congress was put on targeted, radionuclide based therapies. Novel theranostic concepts addressing also tumour entities with high incidence rates such as prostate cancer, melanoma, and lymphoma, have shown effective anti-tumour activity. Strategies have been presented to improve further already established therapeutic regimens such as somatostatin receptor based radio receptor therapy for treating advanced neuroendocrine tumours. Significant contributions were presented also in the neurosciences track. An increasing number of target structures of high interest in neurology and psychiatry are now available for PET and SPECT imaging, facilitating specific imaging of different subtypes of dementia and movement disorders as well as neuroinflammation. Major contributions in the cardiovascular track focused on further optimization of cardiac perfusion imaging by reducing radiation exposure, reducing scanning time, and improving motion correction. Besides coronary artery disease, many contributions focused on cardiac inflammation, cardiac sarcoidosis, and specific imaging of large vessel vasculitis. The physics and instrumentation track included many highlights such as novel, high resolution scanners. The most noteworthy news and developments of this meeting were summarized in the highlights lecture. Only 55 scientific contributions were mentioned, and hence they represent only a brief summary, which is outlined in this article. For a more detailed view, all presentations can be accessed by the online version of the European Journal of Nuclear Medicine and Molecular Imaging (Volume 42, Supplement 1).
KW  - Conjugate arc therapy
KW  - Phase-II
KW  - 18F-FDG PET/CT
KW  - Highlights Lecture
KW  - Molecular Imaging
KW  - Prostate-cancer
KW  - Radionuclide therapy
KW  - Myocardial perfusion
KW  - Preclinical evaluation
KW  - Targeted therapy
KW  - Thyroid cancer
KW  - SPECT
KW  - 2015
KW  - EANM
KW  - Hamburg
KW  - Physics and instrumentation
KW  - Radiopharmacy
KW  - Oncology
KW  - Radionuclide Therapy
KW  - Cardiology
KW  - Neurosciences
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187613
VL  - 43
IS  - 10
ER  -